Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Article Oncology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

S. Peters et al.

Summary: In patients with unresectable malignant pleural mesothelioma, first-line nivolumab plus ipilimumab showed continued long-term survival benefit over chemotherapy with a manageable safety profile, based on 3 years of follow-up data.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer

Benjamin C. Creelan et al.

Summary: This study evaluated the safety and efficacy of Durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC. The results showed that this combination therapy had higher toxicity than using either agent alone, and did not significantly increase progression-free survival compared to historical controls.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

D. M. Vega et al.

Summary: The estimation of TMB varies across different panel assays, with factors like panel size, gene content, and bioinformatics pipelines contributing to empirical variability. Statistical calibration can achieve more consistent results across panels, allowing for comparison of TMB values. A software tool was developed to promote reproducibility and comparability across various assays.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

D. R. Spigel et al.

Summary: Nivolumab did not show survival benefit compared to chemotherapy in relapsed SCLC, but there is a potential survival benefit in certain baseline characteristics.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Patrick M. Forde et al.

Summary: The combination of durvalumab with platinum-based chemotherapy shows promising clinical activity in patients with malignant pleural mesothelioma, leading to improved survival rates. Adverse events during treatment were in line with known side effects of chemotherapy, and immunotherapy-induced adverse reactions were mild.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko et al.

Summary: Maintenance therapy with nivolumab plus ipilimumab did not prolong overall survival (OS) for patients with extensive-disease small-cell lung cancer (ED-SCLC) who did not progress on first-line chemotherapy. However, there may be a benefit of nivolumab plus ipilimumab in patients with a tumor mutational burden of >= 13 mutations per megabase. The rates of grade 3-4 treatment-related adverse events were highest in the nivolumab plus ipilimumab group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer et al.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

添加到收藏夹

Review Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow et al.

Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Tian Tian et al.

Summary: The study found that frontline use of ICIs in EGFR-mutant NSCLC patients provided better survival benefits than later-line use. Combination immunotherapy was more effective than monotherapy. High PD-L1 expression and the EGFR L858R mutation were significantly associated with improved PFS, while a better ECOG status was linked to favorable OS.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

Luis G. Paz-Ares et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Jonathan Spicer et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

Oladimeji Akinboro et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski et al.

Summary: The final analysis of IMpower150 study showed a numerical OS improvement with ACP compared to BCP in metastatic nonsquamous NSCLC patients, while ABCP demonstrated continued OS improvement in all patients.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay

Matthew Evans et al.

PATHOLOGY & ONCOLOGY RESEARCH (2020)

添加到收藏夹

Article Pathology

Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis

Moritz Widmaier et al.

MODERN PATHOLOGY (2020)

添加到收藏夹

Letter Oncology

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer

Karthik Suresh et al.

CLINICAL LUNG CANCER (2020)

添加到收藏夹

Article Oncology

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Jhanelle E. Gray et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs

Aaron R. Hansen et al.

CANCER (2020)

添加到收藏夹

Article Oncology

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study

Roy S. Herbst et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Multidisciplinary Sciences

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis

Jesse Elliott et al.

PLOS ONE (2020)

添加到收藏夹

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

Ticiana Leal et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline

Charles B. Simone et al.

PRACTICAL RADIATION ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

L. Paz-Ares et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Luis Paz-Ares et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

Huy Gia Vuong et al.

TARGETED ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer

Khinh Ranh Voong et al.

CLINICAL LUNG CANCER (2019)

添加到收藏夹

Article Oncology

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

Karthik Suresh et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

James Chih-Hsin Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Assessing the psychosocial needs of newly diagnosed patients with nonsmall cell lung cancer: Identifying factors associated with distress

Bonnie Leung et al.

PSYCHO-ONCOLOGY (2019)

添加到收藏夹

Article Critical Care Medicine

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Oncology

102OFinal analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

T S K Mok et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer

Natasha B. Leighl et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

Hung-Chih Lai et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

Noha Abdel-Wahab et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Oncology

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors

Laura C. Kennedy et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

添加到收藏夹

Article Oncology

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance

Marcus A. Couey et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

Biagio Ricciuti et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Patient Education Issues and Strategies Associated With Immunotherapy

Marlon Lasa-Blandon et al.

SEMINARS IN ONCOLOGY NURSING (2019)

添加到收藏夹

Review Oncology

What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?

Eric G. Nesbit et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)

M. Reck et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Meeting Abstract Oncology

CheckMate 817: First-Line Nivolumab plus Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

F. Barlesi et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Y. -L. Wu et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Respiratory System

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

Yu Nakanishi et al.

RESPIRATORY INVESTIGATION (2019)

添加到收藏夹

Article Medicine, General & Internal

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Alyson Haslam et al.

JAMA NETWORK OPEN (2019)

添加到收藏夹

Article Oncology

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

E. E. Vokes et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

Rodolfo Bordoni et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Article Oncology

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

F. Stephen Hodi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

添加到收藏夹

Article Oncology

NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

添加到收藏夹

Article Oncology

Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer

Sharyn I. Katz et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Samuel G. Armato et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

Louis Fehrenbacher et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Ming Sound Tsao et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V. Long et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Letter Oncology

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

William L. Hwang et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Julie R. Brahmer et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D. Planchard et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Article Oncology

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

Karthik Suresh et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Julie R. Brahmer et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Toshiaki Takahashi et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Review Oncology

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Review Oncology

BAP1 mutations in high-grade meningioma: implications for patient care

Ganesh M. Shankar et al.

NEURO-ONCOLOGY (2017)

添加到收藏夹

Letter Medicine, General & Internal

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

Richard Barnett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond

Lee Pai-Scherf et al.

ONCOLOGIST (2017)

添加到收藏夹

Article Oncology

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Scott Gettinger et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study

Hyojin Kim et al.

ONCOTARGET (2017)

添加到收藏夹

Article Public, Environmental & Occupational Health

Malignant Mesothelioma Mortality — United States, 1999–2015

Jacek M. Mazurek et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)

添加到收藏夹

Article Oncology

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer

David L. Rimm et al.

JAMA ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?

Emily Pulford et al.

DISEASE MARKERS (2017)

添加到收藏夹

Review Oncology

Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review

Paola Queirolo et al.

CANCER TREATMENT REVIEWS (2017)

添加到收藏夹

Article Oncology

Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer

Eleshia J. Morrison et al.

CLINICAL LUNG CANCER (2017)

添加到收藏夹

Article Oncology

Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade

Mike R. Sung et al.

CLINICAL LUNG CANCER (2017)

添加到收藏夹

Review Oncology

CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition

Elizabeth I. Buchbinder et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)

添加到收藏夹

Article Oncology

RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H. Schwartz et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment

Donald R. Sullivan et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gerard Zalcman et al.

LANCET (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst et al.

LANCET (2016)

添加到收藏夹

Article Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott J. Antonia et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

Joohee Sul et al.

ONCOLOGIST (2016)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Quality of life of patients with lung cancer

Jacek Polanski et al.

ONCOTARGETS AND THERAPY (2016)

添加到收藏夹

Review Oncology

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis

Mizuki Nishino et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Meeting Abstract Oncology

PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age

Anita Midha et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

Padmanee Sharma et al.

CELL (2015)

添加到收藏夹

Review Oncology

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR

Eva Regina Haspinger et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)

添加到收藏夹

Editorial Material Oncology

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Surgery

Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database

Robert Ryan Meyerhoff et al.

JOURNAL OF SURGICAL RESEARCH (2015)

添加到收藏夹

Article Pathology

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations

Marta Cigognetti et al.

MODERN PATHOLOGY (2015)

添加到收藏夹

Article Oncology

Population-Based Assessment of Cancer Survivors' Financial Burden and Quality of Life: A Prospective Cohort Study

S. Yousuf Zafar et al.

JOURNAL OF ONCOLOGY PRACTICE (2015)

添加到收藏夹

Review Oncology

Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials

Aaron S. Mansfield et al.

LUNG CANCER (2014)

添加到收藏夹

Review Oncology

Real-world impact of education: treating patients with ipilimumab in a community practice setting

Blanca Ledezma et al.

CANCER MANAGEMENT AND RESEARCH (2014)

添加到收藏夹

Review Oncology

Chemotherapy Education for Patients With Cancer: A Literature Review

Ramsey B. Valenti

CLINICAL JOURNAL OF ONCOLOGY NURSING (2014)

添加到收藏夹

Article Genetics & Heredity

Germline BAP1 Mutations Predispose to Renal Cell Carcinomas

Tatiana Popova et al.

AMERICAN JOURNAL OF HUMAN GENETICS (2013)

添加到收藏夹

Article Oncology

Quality of life during chemotherapy in lung cancer patients: results across different treatment lines

L. M. Wintner et al.

BRITISH JOURNAL OF CANCER (2013)

添加到收藏夹

Article Oncology

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Mizuki Nishino et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Review Immunology

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen et al.

IMMUNITY (2013)

添加到收藏夹

Article Oncology

Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany

Shrividya Iyer et al.

LUNG CANCER (2013)

添加到收藏夹

Article Oncology

The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience

S. Yousuf Zafar et al.

ONCOLOGIST (2013)

添加到收藏夹

Article Oncology

Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer

Linda Sharp et al.

PSYCHO-ONCOLOGY (2013)

添加到收藏夹

Article Clinical Neurology

Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age

Wolfgang Linden et al.

JOURNAL OF AFFECTIVE DISORDERS (2012)

添加到收藏夹

Article Medicine, Research & Experimental

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs

Michele Carbone et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2012)

添加到收藏夹

Article Oncology

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Anna Maria Di Giacomo et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)

添加到收藏夹

Article Oncology

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok et al.

CLINICAL CANCER RESEARCH (2009)

添加到收藏夹

Article Oncology

Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: A literature review

Edward Chow et al.

Current Oncology (2009)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group

S. Burdett et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

F. Stephen Hodi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

添加到收藏夹

Article Oncology

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

F. Stephen Hodi et al.

NATURE CLINICAL PRACTICE ONCOLOGY (2008)

添加到收藏夹

Review Immunology

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Arlene H. Sharpe et al.

NATURE IMMUNOLOGY (2007)

添加到收藏夹

Article Respiratory System

Effect of lung cancer surgery on quality of life

T Win et al.

THORAX (2005)

添加到收藏夹

Review Oncology

The functional assessment of cancer therapy-lung and lung cancer subscale assess quality of life and meaningful symptom improvement in lung cancer

D Cella

SEMINARS IN ONCOLOGY (2004)

添加到收藏夹

Article Oncology

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

NJ Vogelzang et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

添加到收藏夹

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

添加到收藏夹

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

添加到收藏夹

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

相关参考文献